Legend Biotech Corp
Health Care
Current price
Target price 00%
Ranks rating
76
Position in sub-industry
230 / 1361
Position in country
4173 / 14179
Return on Assets, %
-32.7
-40.3
Net income margin, %
-182.3
-180
EBITDA margin, %
-145.7
-168.2
Debt to Equity, %
26.2
3.2
Intangible assets and goodwill, %
0.2
0.2
Revenue CAGR 3Y, %
56
12.5
Total Equity change 1Y, %
68.1
-9
P/BV
7.6
1.8
P/S
33.7
10.3
EV/S
30.3
7.5
EV/EBITDA
-23.7
-1.6
Average Analyst recommendation
Buy
Buy
Average upside forecasts, %
63.4
131.1
Expected dividend per share
0
0
Competitors
Ranks
-
Vertex Pharmaceuticals Inc
00%
-
Regeneron Pharmaceuticals Inc
00%
-
Gilead Sciences Inc
00%
-
Legend Biotech Corp
00%
-
Seagen Inc
00%
-
Amgen Inc
00%
-
Moderna Inc
00%
-
Alnylam Pharmaceuticals Inc
00%
-
AbbVie Inc
00%
-
Biogen Inc
00%
Ready-made portfolio of the best Russian stocks
- Created by artificial intelligence
- Verified by analysts
- Available even to beginners
Company information
Country
United States of America
Sector
Health Care
Industry group
Pharmaceuticals, Biotechnology & Life Sciences
Industry
Biotechnology
Sub-sector
Health Care
Capitalization (millions of $)
9626.7
Ticker
LEGN.O
ISIN
US52490G1022
IPO date
2020-06-04
Availability on Russian exchanges
No
Reporting for
2024-03-19
Date fact. publication of reports
2023-12-31
Company Description
Legend Biotech Corporation. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of cell therapies for oncology and other indications. Its lead product candidate, LCAR- B38M (cilta-cel), is an autologous CAR-T cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in a number of hematologic malignancies, including multiple myeloma (MM). The Company have a portfolio of earlier-stage autologous product candidates targeting various cancers, including Non-Hodgkins Lymphoma (NHL), Acute Myeloid Leukemia (AML), and T cell Lymphoma (TCL). The Company is also developing allogeneic CAR-T product candidates targeting CD20 for the treatment of NHL. It also has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases.
A step towards better analytics
- find the best promotions through the Screener
- keep an eye on stock valuation
- download detailed reports
and much more after free registration
RegistrationMore convenient from your phone? Download: